

Transparency notification BlackRock, Inc.

Brussels (Belgium), 8 July 2025 – 20:00 (CEST) – Regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from BlackRock, Inc. (having its registered office at 50 Hudson Yards, New York, NY, 10001, U.S.A.), on 4 July 2025.


The notification was made following the acquisition or disposal of the control of an undertaking of the BlackRock group that holds a participating interest in UCB.

On 1 July 2025, BlackRock, Inc. (taking into account the holding of its affiliates) owned 10 848 463 UCB shares with voting rights and 118 231 assimilated financial instruments, representing together 5.64% of the total number of shares issued by the company (194 505 658), versus 5.07% (9 725 971 UCB shares and 126 101 assimilated financial instruments) in the previous notification dated 11 March 2025.

2. Content of the notification

- **Reason for the notification:** Acquisition or disposal of the control of an undertaking that holds a participating interest in an issuer.
- **Notification by:** A parent undertaking or a controlling person.
- **Persons subject to the notification requirement:**

Name	Address (for legal entities)
BlackRock, Inc.	50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock (Netherlands) B.V.	Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands
BlackRock (Singapore) Limited	20 Anson Road #18-01, Singapore, 79912, Singapore
BlackRock Advisors (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Advisors, LLC	50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock Asset Management Canada Limited	161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada



BlackRock Asset Management Deutschland AG	Lenbachplatz 1 1st Floor, Munich, 80333-MN3, Germany
BlackRock Asset Management North Asia Limited	15/F, 16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden Road, Central, Hong Kong
BlackRock Financial Management, Inc.	50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock Fund Advisors	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Institutional Trust Company, National Association	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock International Limited	Exchange Place One, 1 Seple Street, Edinburgh, EH3 8BL, U.K.
BlackRock Investment Management (Australia) Limited	Level 37 Chifley Tower, 2 Chifley Square, Sydney NSW 2000, Australia
BlackRock Investment Management (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Investment Management, LLC	1 University Square Drive, Princeton, NJ, 8540, U.S.A.
BlackRock Japan Co., Ltd.	1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217, Japan
Aperio Group, LLC	3 Harbor Dr Suite 204, Sausalito, CA 94965, U.S.A.
SpiderRock Advisors, LLC	Corporation Service Company, 251 Little Falls Drive, Wilmington, DE 19808, U.S.A.

- **Date on which the threshold is crossed:** 1 July 2025.
- **Threshold crossed (in %):** 5%.
- **Denominator:** 194 505 658.

- **Notified details:**

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
BlackRock, Inc.	0	0		0,00%	
BlackRock (Netherlands) B.V.	1.337	3.199		0,00%	
BlackRock (Singapore) Limited	9.601	40.511		0,02%	
BlackRock Advisors (UK) Limited	1.622.142	1.484.160		0,76%	
BlackRock Advisors, LLC	201.535	246.085		0,13%	
BlackRock Asset Management Canada Limited	138.719	142.158		0,07%	
BlackRock Asset Management Deutschland AG	179.060	222.353		0,11%	
BlackRock Asset Management North Asia Limited	3.080	2.994		0,00%	
BlackRock Financial Management, Inc.	73.923	88.642		0,05%	
BlackRock Fund Advisors	2.447.918	2.269.166		1,17%	
BlackRock Institutional Trust Company, National Association	1.601.607	1.565.682		0,80%	
BlackRock International Limited	0	103		0,00	

BlackRock Investment Management (Australia) Limited	51.564	53.544		0,03%	
BlackRock Investment Management (UK) Limited	2.550.434	3.872.002		1,99%	
BlackRock Investment Management, LLC	633.166	660.282		0,34%	
BlackRock Japan Co., Ltd.	170.111	156.867		0,08%	
Aperio Group, LLC	41.774	40.715		0,02%	
Subtotal	9.725.971	10.848.463		5,58%	
	TOTAL	10.848.463	0	5,58%	0,00%

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
BlackRock Financial Management, Inc.	Contract Difference			53.916	0,03%	cash
BlackRock Institutional Trust Company, National Association	Contract Difference			42.315	0,02%	cash
BlackRock Investment Management (UK) Limited	Contract Difference			579	0,00%	cash
BlackRock Advisors (UK) Limited	Depository Receipt			1.537	0,00%	
BlackRock Investment Management (UK) Limited	Depository Receipt			779	0,00%	

Aperio Group, LLC	Depository Receipt			19.063	0,01%	
SpiderRock Advisors, LLC	Depository Receipt			42	0,00%	
	TOTAL			118.231	0,06%	
TOTAL (A & B)				# of voting rights	% of voting rights	
				CALCULATE	10.966.694	5,64%

- **Chain of controlled undertakings through which the holding is effectively held:**
Please see the full chain of control in the 'Chain of Control' tab.
- **Additional information:** As a result of the acquisition of HPS Investment Partners, there has been a change to BlackRock's group structure. Upon the close of the transaction, BlackRock, Inc. contributed all of its equity interests in BlackRock Finance, Inc. and Global Infrastructure Management, LLC to BlackRock Saturn Subco, LLC, a wholly owned subsidiary of the Company.

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following [link](#).

For further information, contact UCB:

Investor Relations
Antje Witte
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications
Laurent Schots
T+32 2 559 92 64
laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news